Close Menu

NEW YORK – Germany-based immuno-oncology company Affimed today announced that it had successfully dosed its first patient with AFM24, an EGFR- and CD16A-binding innate cell engager therapy.

The news marks the start of the company's Phase I/IIb trial of AFM24 in adult patients with EGFR-positive advanced solid tumors. The open-label, non-randomized, multi-center study will assess the maximum tolerated dose of AFM24 as a monotherapy in patients whose disease has progressed after previous lines of treatment, as well as gather preliminary evidence on safety and efficacy.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


NTRK fusions are oncogenic drivers in a variety of tumors.

Sponsored by

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Sponsored by

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.


In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.